Figure 3. Efficacy data based on molecular profiling. Response rate according to the matched treatment in the NEXT-1 trial cohorts.
A. gastrointestinal/hepatobiliary/rare tumor (N = 231) and B. lung cancer cohort (N = 98).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.